---
title: "Livzon Gets Nod to Trial Reflux Esophagitis Drug"
date: "2025-02-13 12:00:16"
summary: "Livzon Pharmaceutical Group , a unit of Joincare Pharmaceutical Group Industry's , obtained the approval of China's National Medical Products Administration to conduct clinical trials on JP-1366 for injection, according to a Hong Kong Stock Exchange filing on Thursday. The drug is currently in phase III trials to be tested..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Livzon Pharmaceutical Group , a unit of Joincare Pharmaceutical Group Industry's , obtained the approval of China's National Medical Products Administration to conduct clinical trials on JP-1366 for injection, according to a Hong Kong Stock Exchange filing on Thursday.

The drug is currently in phase III trials to be tested as a treatment for reflux esophagitis.

The pharmaceutical company spent 5.1 million yuan on the research and development of the drug, the filing said.

Joincare's shares rose more than 1% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250212:G2467142:0/)
